advertising
-
1
Drake LA, Scher RK, Smith EB, et al: Effect of onychomycosis on quality of life. .J Am Acad Dermatol 38::702. ,1998. .
-
2
Scher RK: Onychomycosis: a significant medical disorder. .J Am Acad Dermatol 35::S2. ,1996. .
-
3
Scher RK: Onychomycosis is more than a cosmetic problem. .Br J Dermatol 130: (suppl 43):15. ,1994. .
-
4
Rich P, Schein JR, Lubeck D: Onychomycosis: symptoms and quality of life associated with this medical condition [poster]. Presented at a meeting of the American Academy of Dermatology, July 31–August 4, 1998, Chicago..
-
5
Lubeck DP, Gause D, Schein JR, et al: A health-related quality of life measure for use in patients with onychomycosis: a validation study. .Qual Life Res 8::121. ,1999. .
-
6
Drake L: Quality of life issues for patients with fungal nail infections. .AIDS Patient Care 9: (suppl 1):S15. ,1995. .
-
7
Lubeck DP: Measuring health-related quality of life in onychomycosis. .J Am Acad Dermatol 38::S64. ,1998. .
-
8
Elewski BE: Onychomycosis: pathogenesis, diagnosis, and management. .Clin Microbiol Rev 11::415. ,1998. .
-
9
Cohen PR, Scher RK: Topical and surgical treatment of onychomycosis. .J Am Acad Dermatol 31::S74. ,1994. .
-
10
Arenas R, Domínguez-Cherit J, FernÁndez LM: Open randomized comparison of itraconazole versus terbinafine in onychomycosis. .Int J Dermatol 34::138. ,1995. .
-
11
BrÄutigam M, Nolting S, Schopf RE, et al: Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. .BMJ 311::919. ,1995. .
-
12
DiMatteo MR: Patient adherence to pharmacotherapy: the importance of effective communication. .Formulary 30::596. ,1995. .
-
13
Hiruma M, Matsushita A, Kobayashi M, et al: One week pulse therapy with itraconazole (200 mg day-1) for onychomycosis: evaluation of treatment results according to patient background. .Mycoses 44::87. ,2001. .
-
14
Gupta AK, De Doncker P, Haneke E: Itraconazole pulse therapy for the treatment of Candida onychomycosis. .J Eur Acad Dermatol Venereol 15::112. ,2000. .
-
15
Morisky DE, Green LW, Levine DM: Concurrent and predictive validity of a self-reported measure of medication adherence. .Med Care 24::67. ,1986. .
-
16
Lohr KN, Aaronson NK, Alonso J, et al: Evaluating quality-of-life and health status instruments: development of scientific review criteria. .Clin Ther 18::979. ,1996. .
-
17
Cronbach LJ: Coefficient alpha and the internal structure of tests. .Psychometrika 16::297. ,1951. .
-
18
Sporanox [package insert], Janssen Pharmaceutica, Inc, Titusville, NJ, 2001..
-
19
Lamisil [package insert], Novartis Pharmaceuticals Corp, East Hanover, NJ, 2001..
Satisfaction with Onychomycosis Treatment
Pulse versus Continuous Dosing
Search for other papers by Erin M. Warshaw in
Current site
Google Scholar
PubMed
Search for other papers by Thomas Bowman in
Current site
Google Scholar
PubMed
Search for other papers by Myron A. Bodman in
Current site
Google Scholar
PubMed
Search for other papers by John J. Kim in
Current site
Google Scholar
PubMed
Search for other papers by Stefanie Silva in
Current site
Google Scholar
PubMed
Search for other papers by Susan D. Mathias in
Current site
Google Scholar
PubMed
The purpose of this study, which involved two dermatology clinics and two podiatric medical clinics, was to determine whether a difference exists in patient-reported satisfaction and compliance between continuous terbinafine therapy and pulse-dose itraconazole therapy for the treatment of toenail onychomycosis. Patients in this multicenter, open-label, cross-sectional study had previously completed treatment with either oral terbinafine or oral itraconazole for toenail onychomycosis. Patients were interviewed by telephone to assess clinical outcomes, compliance, and satisfaction with treatment; clinical data were collected by medical chart review. Patients reported significantly greater ease and convenience of treatment and higher overall satisfaction with continuous terbinafine therapy compared with pulse-dose itraconazole therapy. (J Am Podiatr Med Assoc 93(5): 373-379, 2003)
advertising
